Reducing vascular calcification by anti-IL-1β monoclonal antibody in a mouse model of familial hypercholesterolemia

Angiology

Volumn 67, Issue 2, 2016, Pages 157-167

  Awan, Zuhier ^a   Denis, Maxime ^b   Roubtsova, Anna ^c   Essalmani, Rachid ^c   Marcinkiewicz, Jadwiga ^c   Awan, Amani ^a   Gram, Hermann ^d   Seidah, Nabil G ^c   Genest, Jacques ^b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b MCGILL UNIVERSITY   (Canada)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

aortic calcification; familial hypercholesterolemia; IL 1 ; LDLR; PCSK9

Indexed keywords

AMYLOID A PROTEIN; AMYLOID A1 PROTEIN; ANTILIPEMIC AGENT; GAMMA INTERFERON; GLUCOSE; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA ANTIBODY; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; BIOLOGICAL MARKER; IL1B PROTEIN, MOUSE; MONOCLONAL ANTIBODY;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTILIPEMIC ACTIVITY; AORTA FLOW; AORTA STENOSIS; AORTIC TISSUE; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL CALCIFICATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DENSITOMETRY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; FLOW RATE; GLUCOSE BLOOD LEVEL; GROWTH RATE; INFLAMMATION; KIDNEY SIZE; LIVER SIZE; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SPLEEN SIZE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN DIET; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; AORTIC DISEASES; AORTOGRAPHY; BLOOD; BLOOD FLOW; BLOOD FLOW VELOCITY; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ECHOGRAPHY; GENETIC PREDISPOSITION; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; PATHOPHYSIOLOGY; PHENOTYPE; PROCEDURES; VASCULAR CALCIFICATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AORTA; AORTIC DISEASES; AORTOGRAPHY; BIOMARKERS; BLOOD FLOW VELOCITY; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HYPERLIPOPROTEINEMIA TYPE II; INTERLEUKIN-1BETA; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; PROPROTEIN CONVERTASES; RECEPTORS, LDL; REGIONAL BLOOD FLOW; SERINE ENDOPEPTIDASES; VASCULAR CALCIFICATION; X-RAY MICROTOMOGRAPHY;

EID: 84954285668     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319715583205     Document Type: Article

References (49)

1. Awan Z, Alrasadi K, Francis GA, et al. Vascular calcifications in homozygote familial hypercholesterolemia. Arterioscler Thromb Vasc Biol. 2008; 28 (4): 777-785.
2. Alrasadi K, Alwaili K, Awan Z, Valenti D, Couture P, Genest J,. Aortic calcifications in familial hypercholesterolemia: potential role of the low-density lipoprotein receptor gene. Am Heart J. 2009; 157 (1): 170-176.
3. Awan Z, Alwaili K, Alshahrani A, Langsetmo L, Goltzman D, Genest J,. Calcium homeostasis and skeletal integrity in individuals with familial hypercholesterolemia and aortic calcification. Clin Chem. 2010; 56 (10): 1599-1607.
4. Awan Z, Denis M, Bailey D, et al. The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomography. Atherosclerosis. 2011; 219 (2): 455-462.
5. Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008; 48 (2): 646-654.
6. Seidah NG, Prat A,. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov. 2012; 11 (5): 367-383.
7. Fantus D, Awan Z, Seidah NG, Genest J,. Aortic calcification: novel insights from familial hypercholesterolemia and potential role for the low-density lipoprotein receptor. Atherosclerosis. 2013; 226 (1): 9-15.
8. Messika-Zeitoun D, Bielak LF, Peyser PA, et al. Aortic valve calcification: determinants and progression in the population. Arterioscler Thromb Vasc Biol. 2007; 27 (3): 642-648.
9. Kaplan NM, Lieberman E, Neal W,. In Kaplan's Clinical Hypertension. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002: 28-29.
10. Butany J, Collins MJ, Demellawy DE, et al. Morphological and clinical findings in 247 surgically excised native aortic valves. Can J Cardiol. 2005; 21 (9): 747-755.
11. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M,. Burden of valvular heart diseases: a population-based study. Lancet. 2006; 368 (9540): 1005-1011.
12. Akat K, Borggrefe M, Kaden JJ,. Aortic valve calcification: basic science to clinical practice. Heart. 2009; 95 (8): 616-623.
13. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol. 1997; 29 (3): 630-634.
14. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005; 352 (23): 2389-2397.
15. Rossebø AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008; 359 (13): 1343-1356.
16. Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008; 359 (13): 1357-166.
17. Church LD, Cook GP, McDermott MF,. Primer: inflammasomes and interleukin 1beta in inflammatory disorders. Nat Clin Pract Rheumatol. 2008; 4 (1): 34-42.
18. Fearon WF, Fearon DT,. Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. Circulation. 2008; 117 (20): 2577-2579.
19. Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003; 23 (4): 656-660.
20. Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. J Clin Invest. 1996; 97 (3): 769-776.
21. Alexander MR, Murgai M, Moehle CW, Owens GK,. Interleukin-1β modulates smooth muscle cell phenotype to a distinct inflammatory state relative to PDGF-DD via NF-κB-dependent mechanisms. Physiol Genomics. 2012; 44 (7): 417-429.
22. Osborn O, Brownell SE, Sanchez-Alavez M, Salomon D, Gram H, Bartfai T,. Treatment with an interleukin 1 beta antibody improves glycemic control in diet-induced obesity. Cytokine. 2008; 44 (1): 141-148.
23. Baglione J, Smith JD,. Quantitative assay for mouse atherosclerosis in the aortic root. Methods Mol Med. 2006; 129: 83-95.
24. Iijima K, Hashimoto H, Hashimoto M, et al. Aortic arch calcification detectable on chest X-ray is a strong independent predictor of cardiovascular events beyond traditional risk factors. Atherosclerosis. 2010; 210 (1): 137-144.
25. Netea MG, Demacker PN, Kullberg BJ, et al. Increased interleukin-1alpha and interleukin-1beta production by macrophages of low-density lipoprotein receptor knock-out mice stimulated with lipopolysaccharide is CD11c/CD18-receptor mediated. Immunology. 1998; 95 (3): 466-472.
26. Tosi I, Toledo-Leiva P, Neuwirth C, Naoumova RP, Soutar AK,. Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic. Atherosclerosis. 2007; 194 (1): 102-111.
27. Brown MS, Goldstein JL,. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986; 232 (4746): 34-47.
28. Abifadel M, Rabès JP, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009; 30 (4): 520-529.
29. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010; 464 (7293): 1357-1361.
30. Rajamäki K, Lappalainen J, Oörni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One. 2010; 5 (7): e11765.
31. Johnson RC, Leopold JA, Loscalzo J,. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res. 2006; 99 (10): 1044-1059.
32. Miller JD, Weiss RM, Heistad DD,. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res. 2011; 108 (11): 1392-1412.
33. Sage AP, Tintut Y, Demer LL,. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol. 2010; 7 (9): 528-536.
34. Johnson RC, Leopold JA, Loscalzo J,. Vascular calcification: pathobiological mechanisms and clinical implications. Circ Res. 2006; 99 (10): 1044-1059.
35. Shao JS, Cheng SL, Sadhu J, Towler DA,. Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension. 2010; 55 (3): 579-592.
36. Lencel P, Delplace S, Pilet P, et al. Cell-specific effects of TNF-α and IL-1β on alkaline phosphatase: implication for syndesmophyte formation and vascular calcification. Lab Invest. 2011; 91 (10): 1434-1442.
37. Keuylian Z, de Baaij JH, Gueguen M, et al. The Notch pathway attenuates interleukin 1β (IL1β)-mediated induction of adenylyl cyclase 8 (AC8) expression during vascular smooth muscle cell (VSMC) trans-differentiation. J Biol Chem. 2012; 287 (30): 24978-24989.
38. Teo KK, Corsi DJ, Tam JW, Dumesnil JG, Chan KL,. Lipid lowering on progression of mild to moderate aortic stenosis: meta-analysis of the randomized placebo-controlled clinical trials on 2344 patients. Can J Cardiol. 2011; 27 (6): 800-808.
39. Raggi P, Davidson M, Callister TQ, Welty FK, Bachmann GA, Hecht H, Rumberger JA,. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic postmenopausal women: Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES). Circulation. 2005; 112 (4): 563-571.
40. Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008; 10 (3): R67.
41. Weiss RM, Ohashi M, Miller JD, Young SG, Heistad DD,. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation. 2006; 114 (19): 2065-2069.
42. El Husseini D, Boulanger MC, Mahmut A, et al. P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: implication for calcific aortic valve disease. J Mol Cell Cardiol. 2014; 72: 146-56.
43. Elhage R, Maret A, Pieraggi MT, Thiers JC, Arnal JF, Bayard F,. Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice. Circulation. 1998; 97 (3): 242-244.
44. Kirii H, Niwa T, Yamada Y, et al. Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2003; 23 (4): 656-660.
45. Isoda K, Shiigai M, Ishigami N, et al. Deficiency of interleukin-1 receptor antagonist promotes neointimal formation after injury. Circulation. 2003; 108 (5): 516-518.
46. Isoda K, Sawada S, Ishigami N, et al. Lack of interleukin-1 receptor antagonist modulates plaque composition in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2004; 24 (6): 1068-1073.
47. Merhi-Soussi F, Kwak BR, Magne D, et al. Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovasc Res. 2005; 66 (3): 583-593.
48. Chamberlain J, Evans D, King A, et al. Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice. Am J Pathol. 2006; 168 (4): 1396-13403.
49. Ridker PM, Thuren T, Zalewski A, Libby P,. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J. 2011; 162 (4): 597-605.